A trend of increasing TLR9 and IRF1 mRNA expression, associated with a pro-inflammatory, anti-tumor phenotype was observed in BMDMs treated with both RXR agonists (Figure 7C,D). The gene discussed is IRF1; the disease is neoplasm.